AXIN2
Summary: The Axin-related protein, Axin2, presumably plays an important role in the regulation of the stability of beta-catenin in the Wnt signaling pathway, like its rodent homologs, mouse conductin/rat axil. In mouse, conductin organizes a multiprotein complex of APC (adenomatous polyposis of the colon), beta-catenin, glycogen synthase kinase 3-beta, and conductin, which leads to the degradation of beta-catenin. Apparently, the deregulation of beta-catenin is an important event in the genesis of a number of malignancies. The AXIN2 gene has been mapped to 17q23-q24, a region that shows frequent loss of heterozygosity in breast cancer, neuroblastoma, and other tumors. Mutations in this gene have been associated with colorectal cancer with defective mismatch repair. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| axin 2 | MIM:604025 | Ensembl:ENSG00000168646 | HGNC:HGNC:904 | PA25196 | 17q24.1 |
GO terms in AXIN2
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| BP | IEA | GO:0001756 | somitogenesis |
| BP | IMP | GO:0001934 | positive regulation of protein phosphorylation |
| BP | IEA | GO:0003139 | secondary heart field specification |
| BP | IEA | GO:0003413 | chondrocyte differentiation involved in endochondral bone morphogenesis |
| BP | IEA | GO:0008283 | cell proliferation |
| BP | IMP | GO:0008285 | negative regulation of cell proliferation |
| BP | IMP | GO:0010718 | positive regulation of epithelial to mesenchymal transition |
| BP | IMP | GO:0010942 | positive regulation of cell death |
| BP | IEA | GO:0016055 | Wnt signaling pathway |
| BP | IEA | GO:0030282 | bone mineralization |
| BP | IMP | GO:0032423 | regulation of mismatch repair |
| BP | IDA | GO:0034613 | cellular protein localization |
| BP | IMP | GO:0042476 | odontogenesis |
| BP | IEA | GO:0043547 | positive regulation of GTPase activity |
| BP | IMP | GO:0043570 | maintenance of DNA repeat elements |
| BP | IMP | GO:0048255 | mRNA stabilization |
| BP | IEA | GO:0061181 | regulation of chondrocyte development |
| BP | IMP | GO:0070602 | regulation of centromeric sister chromatid cohesion |
| BP | IDA | GO:0090090 | negative regulation of canonical Wnt signaling pathway |
| BP | IMP | GO:0090090 | negative regulation of canonical Wnt signaling pathway |
| BP | TAS | GO:0090263 | positive regulation of canonical Wnt signaling pathway |
| BP | TAS | GO:1904837 | beta-catenin-TCF complex assembly |
| CC | IDA | GO:0005634 | nucleus |
| CC | IDA | GO:0005737 | cytoplasm |
| CC | IDA | GO:0005813 | centrosome |
| CC | TAS | GO:0005829 | cytosol |
| CC | NAS | GO:0030877 | beta-catenin destruction complex |
| MF | IPI | GO:0005515 | protein binding |
| MF | NAS | GO:0008013 | beta-catenin binding |
| MF | IPI | GO:0019899 | enzyme binding |
| MF | IPI | GO:0031625 | ubiquitin protein ligase binding |
| MF | IEA | GO:0070411 | I-SMAD binding |
Gene expression in normal tissue: AXIN2
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in AXIN2
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-195721 | Signaling by WNT |
| reactome | R-HSA-201681 | TCF dependent signaling in response to WNT |
| reactome | R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex |
| reactome | R-HSA-392499 | Metabolism of proteins |
| reactome | R-HSA-4411364 | Binding of TCF/LEF:CTNNB1 to target gene promoters |
| reactome | R-HSA-4641257 | Degradation of AXIN |
| reactome | R-HSA-5688426 | Deubiquitination |
| reactome | R-HSA-5689880 | Ub-specific processing proteases |
| reactome | R-HSA-597592 | Post-translational protein modification |
| pid | betacatenin_deg_pathway | Degradation of beta catenin |
| pid | betacatenin_nuc_pathway | Regulation of nuclear beta catenin signaling and target gene transcription |
| pid | era_genomic_pathway | Validated nuclear estrogen receptor alpha network |
| kegg | hsa04310 | Wnt signaling pathway - Homo sapiens (human) |
| kegg | hsa04390 | Hippo signaling pathway - Homo sapiens (human) |
| kegg | hsa04550 | Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human) |
| kegg | hsa04934 | Cushing,s syndrome - Homo sapiens (human) |
| kegg | hsa05165 | Human papillomavirus infection - Homo sapiens (human) |
| kegg | hsa05200 | Pathways in cancer - Homo sapiens (human) |
| kegg | hsa05210 | Colorectal cancer - Homo sapiens (human) |
| kegg | hsa05213 | Endometrial cancer - Homo sapiens (human) |
| kegg | hsa05217 | Basal cell carcinoma - Homo sapiens (human) |
| kegg | hsa05224 | Breast cancer - Homo sapiens (human) |
| kegg | hsa05225 | Hepatocellular carcinoma - Homo sapiens (human) |
| kegg | hsa05226 | Gastric cancer - Homo sapiens (human) |
| wikipathways | WP2064 | Neural Crest Differentiation |
| wikipathways | WP2773 | Degradation of beta-catenin by the destruction complex |
| wikipathways | WP2857 | Mesodermal Commitment Pathway |
| wikipathways | WP3339 | TCF dependent signaling in response to WNT |
| wikipathways | WP3558 | Beta-catenin independent WNT signaling |
| wikipathways | WP363 | Wnt Signaling Pathway |
| wikipathways | WP3658 | Wnt-beta-catenin Signaling Pathway in Leukemia |
| wikipathways | WP399 | Wnt Signaling Pathway and Pluripotency |
| wikipathways | WP4155 | Endometrial cancer |
| wikipathways | WP4216 | Chromosomal and microsatellite instability in colorectal cancer |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD634 | SCHEMBL2608041 | 7 |
| iGMDRD280 | CYTOCHALASIN B | 1 |
| iGMDRD679 | Bistramide A | 1 |
| iGMDRD297 | Austocystin D | 2 |
| iGMDRD193 | Fqi1 | 1 |
| iGMDRD446 | LY 2183240 | 3 |
| iGMDRD781 | Sirolimus | 5 |
| iGMDRD494 | Neopeltolide | 1 |
| iGMDRD779 | PRL-3 Inhibitor I | 3 |
| iGMDRD144 | NSC95397 | 6 |
| iGMDRD670 | ML 210 | 4 |
| iGMDRD1008 | SR-II-138A | 3 |
| iGMDRD772 | BRD4770 | 6 |
| iGMDRD599 | Salermide | 4 |
| iGMDRD126 | Tipifarnib | 4 |
| iGMDRD524 | ISX-9 | 3 |
| iGMDRD356 | PNU-74654 | 4 |
| iGMDRD369 | TGX-115 | 2 |
| iGMDRD398 | Sepantronium | 3 |
| iGMDRD506 | Fedratinib | 3 |
| iGMDRD399 | Selumetinib | 2 |
| iGMDRD74 | Idarubicin | 3 |
| iGMDRD188 | Piperlongumine | 5 |
| iGMDRD100 | Zebularine | 3 |
| iGMDRD294 | Batimastat | 3 |
| iGMDRD318 | PAC-1 | 2 |
| iGMDRD171 | Pemetrexed | 2 |
| iGMDRD474 | Avrainvillamide | 3 |
| iGMDRD138 | PX 12 | 3 |
| iGMDRD132 | (-)-gallocatechin-3-O-gallate | 3 |
| iGMDRD945 | ML214 | 2 |
| iGMDRD154 | NSC23766 | 2 |
| iGMDRD123 | Isoevodiamine | 2 |
| iGMDRD177 | Teniposide | 4 |
| iGMDRD211 | (1S,3R)-RSL3 | 4 |
| iGMDRD499 | PDMP | 3 |
| iGMDRD351 | GW843682X | 3 |
| iGMDRD698 | Neratinib | 4 |
| iGMDRD150 | RITA | 8 |
| iGMDRD116 | CD437 | 2 |
| iGMDRD512 | nutlin 3 | 7 |
| iGMDRD307 | Manumycin A | 3 |
| iGMDRD84 | Lovastatin acid | 1 |
| iGMDRD82 | Quiflapon | 3 |
| iGMDRD42 | Vorinostat | 3 |
| iGMDRD246 | NPC26 | 3 |
| iGMDRD300 | Tozasertib | 3 |
| iGMDRD329 | Merck60 | 7 |
| iGMDRD872 | BRD7137 | 6 |
| iGMDRD871 | BRD6368 | 3 |
| iGMDRD286 | Nsc 632839 | 3 |
| iGMDRD267 | Oligomycin A | 2 |
| iGMDRD415 | LE-135 | 1 |
| iGMDRD289 | Parthenolide | 3 |
| iGMDRD221 | Tamoxifen | 3 |
| iGMDRD705 | Nakiterpiosin | 2 |
| iGMDRD5 | Tyrphostin AG 1478 | 6 |
| iGMDRD271 | Brefeldin A | 3 |
| iGMDRD158 | NSC141540 | 4 |
| iGMDRD202 | Curcumin | 3 |
| iGMDRD103 | SN-38 | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in AXIN2
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.